Sanders calls on USPTO to block Gilead patent extension

US presidential candidate Bernie Sanders has called on the US Patent and Trademark Office (USPTO) to block extensions to two Gilead Sciences patents covering HIV prevention drugs including Descovy (tenofovir alafenamide/embicitrane).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US government sues Gilead for patent infringement over HIV drugs

7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Americas

Gilead challenges US govt patents on HIV drug Truvada

22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

Americas

Senators demand USPTO probe into Gilead allegations

16 December 2019 The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

More on this story

Americas

US government sues Gilead for patent infringement over HIV drugs

7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Americas

Gilead challenges US govt patents on HIV drug Truvada

22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

Americas

Senators demand USPTO probe into Gilead allegations

16 December 2019 The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

More on this story

Americas

US government sues Gilead for patent infringement over HIV drugs

7 November 2019 The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.

Americas

Gilead challenges US govt patents on HIV drug Truvada

22 August 2019 Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.

Americas

Senators demand USPTO probe into Gilead allegations

16 December 2019 The US Patent and Trademark Office is coming under increasing pressure to review allegations that Gilead delayed development of its latest HIV drug in order to maximise profits.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Sanders calls on USPTO to block Gilead patent extension

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features